Stock listing

ASX:RHY Rhythm Biosciences Limited Share Price

Home listing (ASX) of Rhythm Biosciences Limited

Follow Rhythm Biosciences Limited into a list and get an email when it puts out news.

Share price · ASX:RHY

$0.06 AUD -0.00 (-1.6%)

Close on Nov 20, 2026

Past year -31.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.06 – $0.06 AUDNov 20, 2026
Volume
30,924 sharesNov 20, 2026
Market cap
$21.23M AUDAt the close on Nov 20, 2026 · price × 353.9M shares outstanding
52-week range
$0.06 – $0.28 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$15,659 AUDMedian day 93,119 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Rhythm Biosciences Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:RHY · Home$0.06 AUD-0.001 (-1.6%)30,924$0.06$0.06$0.06$0.061Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:RHY · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.06-0.001-1.6%$0.06$0.06$0.0630,924
$0.0610.000.0%$0.061$0.061$0.06113,530
$0.061-0.002-3.2%$0.064$0.065$0.06133,609
$0.063-0.003-4.5%$0.066$0.066$0.0621,146,494
$0.0660.000.0%$0.067$0.067$0.066102,025
$0.066+0.001+1.5%$0.065$0.066$0.06436,793
$0.065-0.002-3.0%$0.067$0.067$0.065133,743
$0.067-0.002-2.9%$0.067$0.067$0.06766,312
$0.0690.000.0%$0.067$0.069$0.06722,777
$0.069-0.001-1.4%$0.069$0.072$0.06880,339
$0.07+0.007+11.1%$0.068$0.07$0.065171,086
$0.0630.000.0%$0.063$0.063$0.0630
$0.0630.000.0%$0.062$0.063$0.06215,433
$0.0630.000.0%$0.063$0.063$0.06335,843
$0.0630.000.0%$0.063$0.064$0.06290,835
$0.063-0.002-3.1%$0.066$0.066$0.06332,853
$0.0650.000.0%$0.066$0.066$0.065127,191
$0.0650.000.0%$0.065$0.065$0.0650
$0.065-0.003-4.4%$0.068$0.068$0.06538,946
$0.068+0.001+1.5%$0.068$0.068$0.06812,172
$0.0670.000.0%$0.067$0.067$0.0676,090
$0.0670.000.0%$0.069$0.069$0.06793,479
$0.067-0.003-4.3%$0.07$0.071$0.067121,954
$0.07+0.001+1.4%$0.069$0.07$0.067238,639
$0.069+0.002+3.0%$0.061$0.069$0.06824,369
$0.067-0.001-1.5%$0.068$0.068$0.067212,364
$0.068-0.002-2.9%$0.07$0.07$0.06877,226
$0.07-0.006-7.9%$0.073$0.073$0.07304,511
$0.076+0.001+1.3%$0.075$0.076$0.07460,064
$0.075+0.003+4.2%$0.072$0.077$0.072216,340
$0.072-0.004-5.3%$0.078$0.078$0.071264,411
$0.076-0.002-2.6%$0.078$0.08$0.076332,420
$0.078-0.002-1.9%$0.079$0.079$0.077176,881
$0.08-0.001-0.6%$0.08$0.08$0.07746,928
$0.08-0.001-1.2%$0.076$0.08$0.07615,558
$0.0810.000.0%$0.081$0.081$0.08127,186
$0.0810.000.0%$0.081$0.081$0.081,014,505
$0.081-0.002-2.4%$0.083$0.083$0.081421,860
$0.083+0.001+1.2%$0.082$0.083$0.0829,127
$0.0820.000.0%$0.082$0.083$0.08222,558
$0.0820.000.0%$0.082$0.083$0.082143,224
$0.082+0.001+1.2%$0.084$0.084$0.082242,303
$0.081-0.001-1.2%$0.082$0.087$0.0811,240,395
$0.0820.000.0%$0.083$0.083$0.081220,482
$0.0820.000.0%$0.08$0.082$0.0822,105
$0.082+0.002+2.5%$0.081$0.082$0.0833,670
$0.080.000.0%$0.08$0.081$0.0851,808
$0.08-0.002-2.4%$0.082$0.082$0.08259,442
$0.082-0.001-1.2%$0.082$0.082$0.08263,970
$0.083-0.004-4.6%$0.093$0.093$0.083303,147
$0.087+0.005+6.1%$0.085$0.089$0.085128,325
$0.0820.000.0%$0.082$0.082$0.08213,242
$0.082-0.003-3.5%$0.085$0.085$0.082253,634
$0.085-0.002-2.3%$0.084$0.086$0.08486,883
$0.087+0.002+2.4%$0.086$0.088$0.08492,759
$0.085-0.004-4.5%$0.091$0.091$0.08536,209
$0.089-0.005-5.3%$0.093$0.093$0.086461,265
$0.094+0.007+8.0%$0.09$0.094$0.0910,179
$0.087-0.01-10.3%$0.096$0.096$0.087546,322
$0.097-0.001-1.0%$0.099$0.10$0.097128,532
$0.098-0.001-1.0%$0.105$0.105$0.098230,346
$0.099-0.006-5.7%$0.10$0.103$0.097281,526
$0.105+0.017+19.3%$0.093$0.105$0.0911,019,920
$0.0880.000.0%$0.088$0.09$0.08822,461
$0.088+0.001+1.1%$0.087$0.092$0.087288,980
$0.087+0.005+6.1%$0.087$0.087$0.08718,219
Ticker
ASX:RHY
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Rhythm Biosciences Limited news

Rhythm Biosciences Limited on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
34 in the last 12 months · 183 in all · newest Nov 16, 2026 · oldest 2017
Decks
46 decks · latest Nov 4, 2026

Where Rhythm Biosciences Limited is listed

ListingExchangeCountryCurrency
ASX:RHY · Home listing · This pageASXAustraliaAUD
Frankfurt:0RYFrankfurtGermanyEUR

Valuation

EV/sales 211× against a median of 1.8×: the highest of 11 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$18.04M AUD
P/E
Loss
EV/sales
211×
EV/EBITDA
Negative EBITDA
Price/book
5.8×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.1×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Rhythm Biosciences Limited · ASX:RHYUS$14.05MUS$11.94Mn/a211×n/a5.8×n/a0.1×n/a
PlexBio Co., Ltd. · TPEX:6572US$15.79MUS$7.19Mn/a1.9×n/a1.8×−49.1%0.0×n/a
Biosynex SA · EURONEXT:ALBIOUS$15.37MUS$73.75Mn/a0.7×2.3×0.4×−61.1%1.9×n/a
Verici DX PLC · LSE:VRCIUS$15.25MUS$13.61Mn/a3.6×n/a2.6×−189.2%0.1×n/a
Medicon Hellas · ATHEX:MEDICUS$14.99MUS$7.66M7.7×0.4×1.9×0.7×9.8%0.0×n/a
Pharmigene, Inc. · TPEX:7595US$14.70MUS$29.38Mn/a4.8×n/a1.9×−36.5%2.2×n/a
BCAL Diagnostics Limited · ASX:BDXUS$14.64MUS$18.17Mn/a150×n/an/an/an/an/a
Noul Co Ltd. · KRX:376930US$14.03MUS$6.23Mn/a1.6×n/a1.1×−389.6%0.0×n/a
Telescope Innovations Corp · CSE:TELIUS$13.52MUS$12.59Mn/a2.5×n/a5.7×−56.0%0.0×1.20
LabGenomics Co., Ltd. · KRX:084650US$13.28MUS$2.59Mn/a0.0×n/a0.1×−66.5%0.1×n/a
IDT Australia Limited · ASX:IDTUS$13.09MUS$18.52Mn/a1.4×n/a1.0×−13.4%0.6×n/a
Median of the othersUS$14.67MUS$13.10M7.7×1.8×2.0×1.1×−56.0%0.1×1.20

Team and board

Officers

OfficerRole
David AtkinsChief Executive Officer & Managing Director
Andrea SteeleLegal Counsel
Adam ZembrzuskiChief Commercial Officer
Erika SpaethDirector of Clinical & Scientific Affairs
Gary GohDirector of Operations and Quality

Board

DirectorRole
Sue MacLeman BPharm LLM MMktg FTSENon-Executive Interim Chair
Carl StubbingsNon-Executive Director
Maureen BakerNon-Executive Director

Events

QuarterResultsShare move
Q2 2026Feb 18, 2026+2.4%
Q4 2025Aug 29, 2025−9.0%
Q2 2025Feb 20, 2025−1.0%
Q2 2023Feb 23, 2023 · After close+3.7%
Q4 2022Aug 29, 2022 · After close−1.5%
Q2 2022Feb 24, 2022 · After close+1.9%
Q4 2021Aug 31, 2021+1.6%
Q2 2021Feb 24, 2021+4.3%

Open Events

Decks

DeckKindSlidesDate
Q1 FY27 Earnings PresentationEarnings18 slidesNov 4, 2026
20th Bioshares Biotech Summit 2026Conference15 slidesAug 6, 2026
Accreditation Matters Conference 2026Conference15 slidesJul 7, 2026
Investor Presentation (June 2026)Investor deck19 slidesJun 4, 2026
Corporate Update (May 2026)Corporate update9 slidesMay 13, 2026
Investor Presentation (March 2026)Investor deck14 slidesMar 18, 2026
Investor Presentation (February 2026)Investor deck19 slidesFeb 16, 2026
Invest & Connect Event (November 2025)Conference4 slidesNov 26, 2025
Shareholder Meeting (November 2025)Shareholder meeting15 slidesNov 5, 2025
Non-Deal Roadshow (October 2025)Roadshow21 slidesOct 10, 2025
All 46 decks
DeckKindSlidesDate
Investor Presentation (August 2025)Investor deck14 slidesAug 18, 2025
Investor Presentation (June 2025)Investor deck30 slidesJun 19, 2025
Non-Deal Roadshow (June 2025)Roadshow17 slidesJun 2, 2025
Shareholder Meeting (March 2025)Shareholder meeting19 slidesMar 31, 2025
Shareholder Meeting (November 2024)Shareholder meeting22 slidesNov 20, 2024
Investor Presentation (November 2024)Investor deck19 slidesNov 19, 2024
Investor Presentation (October 2024)Investor deck19 slidesOct 24, 2024
Bioshares Biotech Summit 2024Conference17 slidesJul 12, 2024
Investor Presentation (February 2024)Investor deck20 slidesFeb 21, 2024
Shareholder Meeting (February 2024)Shareholder meeting5 slidesFeb 12, 2024
Shareholder Meeting (October 2023)Shareholder meeting13 slidesOct 10, 2023
Bioshares Summit 2023Conference20 slidesJul 25, 2023
Investor Presentation (June 2023)Investor deck18 slidesJun 20, 2023
Investor Presentation (February 2023)Investor deck24 slidesFeb 23, 2023
Investor Presentation (January 2023)Investor deck24 slidesJan 25, 2023
Investor Presentation (December 2022)Investor deck24 slidesDec 15, 2022
MST Access Diagnostics Forum 2022Conference26 slidesDec 6, 2022
MST Access Diagnostics Forum 2022Conference24 slidesDec 6, 2022
Shareholder Meeting (November 2022)Shareholder meeting12 slidesNov 29, 2022
Bell Potter Healthcare Conference 2022Conference24 slidesNov 9, 2022
PAC Partners Inaugural Healthcare Conference 2022Conference14 slidesApr 6, 2022
Investor Presentation (April 2022)Investor deck12 slidesApr 5, 2022
Investor Presentation (March 2022)Investor deck12 slidesMar 2, 2022
Shareholder Meeting (November 2021)Shareholder meeting15 slidesNov 24, 2021
Investor Presentation (November 2021)Investor deck29 slidesNov 10, 2021
Investor Presentation (October 2021)Investor deck29 slidesOct 25, 2021
Investor Presentation (October 2021)Investor deck29 slidesOct 25, 2021
Investor Presentation (July 2021)Investor deck33 slidesJul 30, 2021
MST Access Australian Micro & Small Caps Conference 2021Conference29 slidesJun 17, 2021
Investor Presentation (December 2020)Investor deck28 slidesDec 21, 2020
Investor Presentation (November 2020)Investor deck28 slidesNov 19, 2020
Shareholder Meeting (November 2020)Shareholder meeting13 slidesNov 18, 2020
Shareholder Meeting (October 2019)Shareholder meeting16 slidesOctober 2019
Investor Presentation (July 2019)Investor deck21 slidesJuly 2019
Investor Presentation (February 2019)Investor deck19 slidesFeb 11, 2019
Shareholder Meeting (November 2018)Shareholder meeting14 slidesNov 26, 2018

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue85.3K3.19M1.69M3.10M2.43M1.11M100.0K1.03M64.5K0
Cost of revenue4.48M224.9K3.05M189.4K101.5K146.6K141.3K65.4K31.5K0
Gross profit-4.40M2.97M-1.36M2.91M-101.5K961.9K-41.3K962.3K-31.5K0
Research and development1.04M1.38M2.35M3.65M5.16M4.55M1.94M980.3K359.1K299.5K
Selling, general and administrative5.95M1.67M1.41M7.33M5.33M2.97M2.00M2.28M1.13M422.0K
Operating income-7.46M-3.53M-6.71M-11.5M-8.72M-6.48M-3.92M-3.71M-1.60M-72.1K
Depreciation and amortization189.3K196.9K198.7K189.4K101.5K146.6K141.3K65.4K31.5K805.5K
EBITDA-7.27M-3.34M-6.51M-11.4M-8.62M-6.33M-3.78M-3.65M-1.57M733.4K
Interest expense74.8K66.7K3.14K25.0K3967.80K000
Income before tax-7.51M-3.83M-8.55M-8.22M-8.79M-6.61M-4.02M-2.55M-1.75M-866.0K
Income tax-1.58M-1.69M-228.0K-2.41M1.11M107.8K-1.17M124.8K-806.0K
Net income-5.93M-3.83M-6.86M-8.22M-8.79M-6.61M-4.02M-2.55M-1.75M-72.1K
Earnings per share, basic-0.02-0.01-0.03-0.04-0.04-0.04-0.03-0.02-0.02-0.00

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents3.36M1.40M709.5K4.12M7.55M2.23M1.80M4.73M7.78M1.49M
Short-term investments85.0K85.0K45.0K45.0K45.0K45.0K45.0K45.0K45.0K
Receivables64.3K61.9K37.2K65.5K82.4K164.0K139.2K797.7K35.2K4.37K
Inventory16.3K74.4K57.8K2.77M-1.00K
Current assets3.76M1.81M886.7K7.12M7.77M2.49M2.01M5.61M7.87M1.50M
Property, plant and equipment171.0K113.2K104.9K240.7K113.8K142.6K90.2K9.30K
Goodwill531.0K531.0K
Total assets4.78M2.83M1.52M7.70M8.44M3.07M2.65M6.23M8.45M1.55M
Accounts payable332.9K529.6K211.6K1.33M278.3K603.2K560.5K207.2K79.3K48.5K
Current liabilities1.04M2.16M561.8K1.77M932.4K1.34M794.4K373.0K147.4K126.5K
Total debt248.0K1.11M163.8K84.6K170.1K42.4K
Total liabilities1.14M2.17M651.5K1.82M1.07M1.36M802.9K379.7K147.4K126.5K
Shareholders' equity3.64M659.9K867.2K5.87M7.37M1.71M1.84M5.85M8.30M1.42M
Shares outstanding334.2M269.3M228.3M221.5M214.4M185.2M117.9M117.9M91.2M117.9M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-5.23M-2.92M-6.14M-6.96M-6.21M-5.40M-2.74M-2.94M-1.65M-13
Capital spending-25.8K-23.2K-82.3K-99.1K-27.0K-68.3K-45.5K-110.3K-310.8K-10.8K
Free cash flow-5.26M-2.94M-6.22M-7.06M-6.24M-5.47M-2.79M-3.05M-1.96M-13
Cash from investing-22.8K-583.0K-82.3K-99.1K-27.0K-68.3K-45.5K-110.3K-355.8K-355.8K
Cash from financing7.22M4.19M2.80M3.63M11.8M5.90M-142.2K-142.2K8.29M1.50M
Share buybacks-536.0K3.50M-117.9K-24.2K-467.9K-225.1K0-750.3K1.50M
Change in cash1.96M687.7K-3.41M-3.43M5.32M430.4K-2.93M-3.05M6.29M1.49M

Open Financials

Filings

FilingDateTypeFiled with
Rhythm Appoints Adam Zembrzuski as Chief Commercial OfficerNov 16, 2026Management or board changeASX
Commercial Update-Expansion of ColoSTAT ordering capabilityNov 4, 2026Operations updateASX
RHY Q1 FY27 UpdateNov 3, 2026Quarterly reportASX
Quarterly Activities Report and Appendix 4COct 26, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 26, 2026Meeting noticeASX
ColoSTAT Economic Study - Australian Public Health SavingsOct 6, 2026Operations updateASX
Final Director's Interest Notice - Gavin Fox-SmithSep 30, 2026Ownership change noticeASX
FY26 Appendix 4G and Corporate Governance StatementSep 29, 2026Annual reportASX
FY26 Annual ReportSep 29, 2026Annual reportASX
AGM date and closing date for director nominationsSep 28, 2026Meeting noticeASX
All 176 filings
FilingDateTypeFiled with
Board ChangesSep 28, 2026Management or board changeASX
Initial ColoSTAT Assessment in UK opens new market accessSep 21, 2026Operations updateASX
Initial Director's Interest Notice - Carl StubbingsAug 28, 2026Ownership change noticeASX
Initial Director's Interest Notice - Maureen BakerAug 28, 2026Ownership change noticeASX
FY26 Appendix 4E & Audited Financial ReportAug 27, 2026ResultsASX
Appointment of Non-Executive DirectorsAug 25, 2026Management or board changeASX
Notification of cessation of securities - RHYAug 20, 2026FinancingASX
ColoSTAT Commercial Rollout UpdateAug 19, 2026Operations updateASX
Bioshares 2026 PresentationAug 5, 2026Other filingsASX
Quarterly Activities Report and Appendix 4CJul 29, 2026Quarterly reportASX
Response to ASX Query LetterApr 14, 2026Explanation requestASX
First ColoSTAT Clinical Test SaleMar 10, 2026Operations updateASX
NATA Accredits ColoSTAT Clinical Testing ServiceMar 8, 2026Operations updateASX
RHY Executes SE Asian Genetype Distribution AgreementMar 3, 2026Operations updateASX
Exercise of RHYO Options underwritten for $4.5m to $6.0mFeb 24, 2026FinancingASX
Trading HaltFeb 22, 2026Trading halt or suspensionASX
Half-Year Financial Report and Appendix 4DFeb 18, 2026Interim reportASX
Rhythm Bio enters ColoSTAT agreement with 4Cyte PathologyFeb 16, 2026Operations updateASX
ColoSTAT commercial deployment - First physician enrolledFeb 10, 2026Operations updateASX
Rhythm Biosciences Signs Manufacturing AgreementFeb 2, 2026Material contractASX
Quarterly Activities Report and Appendix 4CJan 22, 2026Quarterly reportASX
Rhythm Initiates Commercialisation of ColoSTATDec 11, 2025Operations updateASX
Appendix 4C and Market UpdateOct 28, 2025Quarterly reportASX
Appendix 4EAug 29, 2025ResultsASX
Strategic partnership with Know Your Lemons FoundationAug 27, 2025Operations updateASX
ColoSTAT Kit Validation Completion and NATA SubmissionAug 25, 2025Operations updateASX
Placement ProspectusAug 18, 2025Offer documentASX
Share Placement to Raise Up To $3.75 millionAug 17, 2025FinancingASX
Placement Issue Investor PresentationAug 17, 2025FinancingASX
Response to ASX Price QueryAug 6, 2025Explanation requestASX
ColoSTAT Kits Deliver Breakthrough ResultsAug 3, 2025Operations updateASX
Jun 25 Quarterly Activities Report and Appendix 4CJul 30, 2025Quarterly reportASX
FY2025 R&D Tax Incentive Loan FundingJun 30, 2025Other filingsASX
NATA Accreditation Awarded for Genetype LaboratoryJun 23, 2025Operations updateASX
ColoSTAT Beta kit verification and validation updateMay 25, 2025Operations updateASX
Breast Cancer Risk Study University of MelbourneMay 14, 2025Operations updateASX
Quarterly Activities Report and Appendix 4C 31 March 2025Apr 23, 2025Quarterly reportASX
EGM - Investor PresentationMar 30, 2025Other filingsASX
RHY Genetype Commercial SalesMar 18, 2025ResultsASX
RHY Investor WebinarMar 4, 2025Other filingsASX
Genetype Commercial Integration CompletionFeb 3, 2025Operations updateASX
Quarterly Activities Report and Appendix 4C - Dec24Jan 22, 2025Quarterly reportASX
About the Genetype AcquisitionJan 13, 2025Acquisition or disposalASX
Completion of Genetype Risk Assessment Portfolio AcquisitionDec 23, 2024Acquisition or disposalASX
RHY Acquires Genetype Genetic Risk Assessment BusinessDec 22, 2024Acquisition or disposalASX
Pause in TradingDec 20, 2024Trading halt or suspensionASX
Market Update - All End of CY24 Milestones AttainedDec 17, 2024Operations updateASX
Strong Demand in Share Placement to Raise $3.5 millionNov 18, 2024FinancingASX
Receipt of Research & Development Tax IncentiveNov 6, 2024Other filingsASX
2nd Generation, ColoSTAT Multiplex Alpha Kit OutperformsOct 6, 2024Operations updateASX
Board Renewal / Composition UpdateSep 29, 2024Management or board changeASX
Platform Expansion - Gastric Cancer Diagnostic Test UpdateSep 23, 2024Operations updateASX
Product and Market Update - Phase 2 MilestoneAug 27, 2024Operations updateASX
Jun 24 Quarterly Activities Report and Appendix 4CJul 28, 2024Quarterly reportASX
Mar24 Quarterly Activities Report and Appendix 4CApr 29, 2024Quarterly reportASX
Dr David Atkins appointed Chief Executive Officer of RhythmApr 24, 2024Management or board changeASX
Rhythm Maintains ISO CertificationApr 22, 2024Other filingsASX
Close of Rights IssueMar 20, 2024FinancingASX
Internationally Renowned Clinical Advisory Board EstablishedMar 18, 2024Operations updateASX
S&P DJI Announces March 2024 Quarterly RebalanceMar 1, 2024Other filingsASX
Half Yearly Report and AccountsFeb 28, 2024Interim reportASX
Prospectus - 2024 Non-Renounceable Rights IssueFeb 18, 2024Offer documentASX
Rights Issue Offer to Raise Up To $6.6 millionFeb 8, 2024FinancingASX
Quarterly Activities Report and Appendix 4C - Dec23Jan 30, 2024Quarterly reportASX
Strategy & Market UpdateDec 17, 2023Operations updateASX
Platform Expansion - Lung Cancer Diagnostic Test UpdateNov 23, 2023Operations updateASX
Executive Management ChangesNov 15, 2023Management or board changeASX
Receipt of First Tranche of $1.69m in R&D Tax IncentiveNov 13, 2023FinancingASX
Response to ASX QueryOct 18, 2023Explanation requestASX
RHY 2023 AGM PresentationOct 9, 2023Other filingsASX
Investor PresentationJun 19, 2023Other filingsASX
UK Strategic Partnership with LINK Medical SolutionsMay 24, 2023Other filingsASX
UK CA Mark granted for ColoSTATMay 16, 2023Other filingsASX
Executive Management ChangeApr 19, 2023Other filingsASX
ColoSTAT abstracts accepted at 2023 ASCO Annual MeetingApr 6, 2023Other filingsASX
Reinstatement to Official QuotationMar 5, 2023Trading halt or suspensionASX
Update to TGA SubmissionMar 5, 2023Other filingsASX
Suspension from Official QuotationMar 3, 2023Trading halt or suspensionASX
Appendix 4D & Interim Financial ReportFeb 23, 2023Interim reportASX
RHY Institutional PresentationFeb 23, 2023Other filingsASX
Appendix 4C - QuarterlyJan 31, 2023Quarterly reportASX
Institutional PresentationJan 24, 2023Other filingsASX
Market UpdateDec 14, 2022Other filingsASX
RHY Continues Platform Expansion Program for Other CancersDec 14, 2022Other filingsASX
MST Access Diagnostics Forum Presentation (Amended)Dec 6, 2022Other filingsASX
MST Access Financial Diagnostics PresentationDec 5, 2022Other filingsASX
RHY 2022 AGM PresentationNov 29, 2022Other filingsASX
Healthcare Conference Investor PresentationNov 8, 2022Other filingsASX
ColoSTAT Authorised For Sale In New ZealandNov 2, 2022Other filingsASX
Rhythm Receives $2.7m R&D Tax IncentiveOct 20, 2022Other filingsASX
Director Share Sale To Institutional Funds ManagerSep 8, 2022Other filingsASX
RHY Advances Platform Expansion with Other CancersJul 18, 2022Other filingsASX
Completion of Final TGA Submission Step to Approve ColoSTATMay 11, 2022Other filingsASX
Rhythm Closes Final Clinical Trial SiteMay 3, 2022Other filingsASX
Appendix 4C - quarterlyApr 27, 2022Quarterly reportASX
Rhythm Biosciences - Investor PresentationApr 4, 2022Other filingsASX
Study 7 Confirms ColoSTAT Meets Primary EndpointApr 3, 2022Other filingsASX
S&P DJI Announces March 2022 Quarterly RebalanceMar 4, 2022Other filingsASX
Rhythm Biosciences - Investor Webinar PresentationMar 1, 2022Other filingsASX
Appendix 4D and Half Yearly Report and AccountsFeb 24, 2022Interim reportASX
Rhythm Maintains Ongoing ISO13485 CertificationFeb 14, 2022Other filingsASX
Placement of $6.5m to Global Institutional Funds ManagerJan 5, 2022FinancingASX
RHY Platform Technology Targets Five CancersDec 13, 2021Other filingsASX
Board and Management RestructureNov 30, 2021Other filingsASX
CE Mark Granted for ColoSTATNov 29, 2021Other filingsASX
ColoSTAT Test Kits Deliver Consistent, High Accuracy ResultsOct 20, 2021Other filingsASX
Rhythm Receives $2.4m R&D Tax IncentiveOct 4, 2021Other filingsASX
Rhythm Completes Recruitment for Clinical Trial (Study 7)Sep 21, 2021Other filingsASX
TGA Accepts Initial Regulatory DocumentationSep 14, 2021Other filingsASX
Rhythm Completes Strongly Oversubscribed $4.3M Rights IssueSep 7, 2021FinancingASX
Initial TGA Regulatory Documentation SubmittedAug 18, 2021Other filingsASX
Non Renounceable pro rata offer - Completion of despatchAug 9, 2021Other filingsASX
Rights Issue Investor PresentationJul 30, 2021FinancingASX
Non renouneable rights issue prospectusJul 29, 2021FinancingASX
Rhythm Establishes US Entity To Drive US Expansion StrategyJul 14, 2021Other filingsASX
Rhythm to Present at MST Access Investor ConferenceJun 17, 2021Other filingsASX
RHY adds Sonic Clinical Services to ColoSTAT Clinical TrialJun 15, 2021Other filingsASX
FY22 Strategic UpdateMay 17, 2021Other filingsASX
Rhythm Betters ColoSTAT ResultsMay 5, 2021Other filingsASX
Rhythm Extends ColoSTAT Clinical Trial to Western AustraliaApr 12, 2021Other filingsASX
Rhythm Retains ISO13485 CertificationMar 30, 2021Other filingsASX
Study 6 Successfully Concluded - Exceptional ResultsMar 15, 2021Other filingsASX
Rhythm Expands ColoSTAT Clinical Trial To Tenth SiteFeb 10, 2021Other filingsASX
Initial Manufacturing of ColoSTAT Test-Kits CompleteJan 19, 2021Other filingsASX
Rhythm Advances ColoSTAT Study 7Jan 18, 2021Other filingsASX
Investor Presentation - December 2020Dec 20, 2020Other filingsASX
Rhythm Secures US Patent - Strengthens Global FootprintDec 16, 2020Other filingsASX
Rhythm Appoints Global Manufacturer for ColoSTATDec 1, 2020Other filingsASX
AGM Presentation - November 2020Nov 17, 2020Other filingsASX
ColoSTAT Prototype Complete, Outperforms FITNov 11, 2020Other filingsASX
Ethics Approval Received, New Clinical Trial Site AddedOct 26, 2020Other filingsASX
Rhythm Receives $1.1m R&D Tax IncentiveOct 15, 2020Other filingsASX
Final Two Adjunct Biomarkers Technically ValidatedSep 28, 2020Other filingsASX
New Clinical Trial Site Contracted and RecruitingSep 22, 2020Other filingsASX
Rhythm Successfully Validates Two Adjunct BiomarkersSep 15, 2020Other filingsASX
Revised CEO Contract and LTIP for all employees - amendedSep 14, 2020Other filingsASX
Revised CEO Contract and LTIP initiated for all employeesSep 13, 2020Other filingsASX
Addtl Clinical Trial Site Signed - First Patient RecruitedSep 9, 2020Other filingsASX
Non-renounceable rights issue OfferJul 31, 2020FinancingASX
Placement & Rights Offer to raise approximately $6 millionJul 22, 2020FinancingASX
COVID-19 UpdateApr 8, 2020Other filingsASX
Successful ISO13485 Surveillance AuditApr 5, 2020Other filingsASX
Rhythm Successfully Validates Key BiomarkerApr 1, 2020Other filingsASX
Rhythm Biosciences Granted China PatentNov 3, 2019Other filingsASX
ColoSTAT - Test Development UpdateSep 19, 2019Other filingsASX
Appendix 4CJul 25, 2019Quarterly reportASX
Rhythm signs Alfred Hospital for ColoSTAT clinical trialJun 26, 2019Other filingsASX
Monash Health signed with first patients recruitedJun 17, 2019Other filingsASX
Rhythm Biosciences receives ISO certificationMay 21, 2019Other filingsASX
Rhythm recruits first patient in ColoSTAT clinical trialMar 17, 2019Other filingsASX
RHY Signs first ColoSTAT site for Clinical Trial - Study 7Feb 19, 2019Other filingsASX
Corporate PresentationFeb 10, 2019Other filingsASX
Rhythm Completes Reagent Development ProgramDec 4, 2018Other filingsASX
Appointment of CEO - Senior Management ChangesNov 27, 2018Management or board changeASX
AGM PresentationNov 25, 2018Other filingsASX
Final Antibody Selection CompleteOct 2, 2018Other filingsASX
Rhythm completes cloning of key reagent ahead of scheduleJun 20, 2018Other filingsASX
Rhythm Granted Biomarker Patent in EuropeMay 16, 2018Other filingsASX
RHYs Four Antibodies Pass all Three Key Screening TestsMay 14, 2018Other filingsASX
Reagent Development UpdateApr 23, 2018Other filingsASX
Appendix 4D - Half Yearly ReportFeb 28, 2018Interim reportASX
Rhythm reports reagent development updateFeb 7, 2018Other filingsASX
Quarterly report and Appendix 4CJan 30, 2018Quarterly reportASX
CSIRO and Rhythm Commence Development of Key ReagentsJan 24, 2018Other filingsASX
CSIRO to assist Rhythm Biosciences develop key reagentsJan 8, 2018Other filingsASX
Admission to Official ListDec 6, 2017Other filingsASX

Open Filings

Cap table

Built by 6ix from Rhythm Biosciences Limited’s releases

Common shares
353,866,857
Fully diluted
353,866,857

Fully diluted

LineShares
Common shares353,866,857

Share count over time

CountShares
Nov 22, 2026353,866,857

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Adam ZembrzuskiChief Commercial Officer · Since Nov 16, 2026
Andrea SteeleLegal Counsel · Since at least Nov 18, 2026
Carl StubbingsNon-Executive Director · Since at least Nov 18, 2026
David AtkinsChief Executive Officer & Managing Director · Since at least Dec 22, 2025
Erika SpaethDirector of Clinical & Scientific Affairs · Since at least Jan 14, 2026
Gary GohDirector of Operations and Quality · Since at least Nov 18, 2026
Maureen BakerNon-Executive Director · Since at least Nov 18, 2026
Sue MacLeman BPharm LLM MMktg FTSENon-Executive Interim Chair · Since at least Nov 18, 2026

Open People

Log in to ask 6ix AI your own questions about Rhythm Biosciences Limited.